Cingulate (CING) Operating Income (2021 - 2026)
Cingulate's (CING) quarterly Operating Income came in at -$5.6 million in Q4 2025, up 10.02% YoY from -$5.1 million in Q4 2024, and up 6.83% on a QoQ basis from -$6.0 million in Q3 2025.
Cingulate (CING) Operating Income (2021 - 2026) Analysis & Trends
Cingulate (CING) has 5 years of Operating Income data on file, last reported at -$5.6 million in Q4 2025.
- Quarterly Operating Income rose 10.02% year-over-year to -$5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$21.5 million (down 37.4% YoY) and the FY2025 annual result came in at -$19.9 million, down 27.44% from the prior year.
- Operating Income advanced to -$5.6 million in Q4 2025, from -$6.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$1.3 million in Q1 2021 to a low of -$15.3 million in Q3 2021.
- A 5-year average of -$4.8 million and a median of -$4.0 million in 2022 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 74.03% in 2022, down 276.6% in 2022.
- Tracing CING's Operating Income over 5 years: stood at -$2.6 million in 2021, then slumped by 69.05% to -$4.5 million in 2022, then sank by 51.89% to -$6.8 million in 2023, then climbed by 8.66% to -$6.2 million in 2024, then rose by 10.02% to -$5.6 million in 2025.
- The last three Operating Income figures came in at -$5.6 million (Q4 2025), -$6.0 million (Q3 2025), and -$3.7 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Cingulate | 70.68 Mn | 70.68 Mn | - | -5.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.41 Mn |
| Dec 31, 2025 | -5.59 Mn |
| Sep 30, 2025 | -6.00 Mn |
| Mar 31, 2025 | -3.71 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Sep 30, 2024 | -3.28 Mn |
| Jun 30, 2024 | -3.21 Mn |
| Mar 31, 2024 | -2.95 Mn |
| Dec 31, 2023 | -6.80 Mn |
| Sep 30, 2023 | -5.75 Mn |
| Jun 30, 2023 | -6.36 Mn |
| Mar 31, 2023 | -3.85 Mn |
| Dec 31, 2022 | -4.48 Mn |
| Sep 30, 2022 | -3.97 Mn |
| Jun 30, 2022 | -4.05 Mn |
| Mar 31, 2022 | -5.01 Mn |
| Dec 31, 2021 | -2.65 Mn |
| Sep 30, 2021 | -15.28 Mn |
| Jun 30, 2021 | -1.42 Mn |
| Mar 31, 2021 | -1.33 Mn |